Reprint
Monoclonal Antibody-Directed Therapy
Edited by
January 2022
142 pages
- ISBN978-3-0365-2873-1 (Hardback)
- ISBN978-3-0365-2872-4 (PDF)
This book is a reprint of the Special Issue Monoclonal Antibody-Directed Therapy that was published in
Biology & Life Sciences
Summary
The book deals with therapeutic monoclonal antibodies (mAbs) broadly, and relevant topics such as challenges and opportunities, next-generation antibody products, Antibody-Drug-Conjugates (ADC), bispecifics, glycosylation, and T-cell engagers are covered. Each topic has been written by leading groups around the world and the book should be of interest to researchers from both academia and industry.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
therapeutic antibody; stability; aggregation; manufacture challenges; formulation; antibodies; site-specific conjugation; bioconjugates; ADC; antibody-drug conjugates; payloads; linkers; nucleic acids; ADME; developability; formulation; glycosylation; post-translational modifications; pharmacokinetics; effector functions; antibody-dependent cell-mediated cytotoxicity; complement-dependent cytotoxicity; immunogenicity; pharmacodynamics; glycoengineering; antibody-drug conjugates; type III secretion system; antibodies; prophylaxis; antibacterials; antibiotics; HIV/AIDS; co-formulation; high concentration; analytical characterization; antibody (s); T-cell engagers; bispecific antibodies; immunotherapy; oncology; antibody engineering; immunological synapse